Validation of a rapid type 1 diabetes autoantibody screening assay for community-based screening of organ donors to identify subjects at increased risk for the disease

Clinical and Experimental Immunology

Volumn 185, Issue 1, 2016, Pages 33-41

  Wasserfall, C ^a   Montgomery, E ^a   Yu, L ^b   Michels, A ^b   Gianani, R ^c   Pugliese, A ^d   Nierras, C ^e,h   Kaddis, J S ^f   Schatz, D A ^a   Bonifacio, E ^g   Atkinson, M A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ROCKY VISTA UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e JDRF   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

autoantibodies; nPOD; organ donor; screening; type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES RAPID TEST; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; ORGAN DONOR; PRIORITY JOURNAL; RAPID TEST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VALIDATION STUDY;

EID: 84974803126     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12797     Document Type: Article

References (34)

1. Campbell-Thompson M, Wasserfall C, Kaddis J et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev 2012; 28:608–17.
2. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48:460–8.
3. Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:2269–74.
4. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52:1128–36.
5. Lampasona V, Schlosser M, Mueller PW et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011; 57:1693–702.
6. Bonifacio E, Lernmark A, Dawkins RL. Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies. J Immunol Methods 1988; 106:83–8.
7. Gleichmann H, Bottazzo GF. Progress toward standardization of cytoplasmic islet cell-antibody assay. Diabetes 1987; 36:578–84.
8. Hagopian WA, Sanjeevi CB, Kockum I et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest 1995; 95:1505–11.
9. Maclaren NK, Lan MS, Schatz D, Malone J, Notkins AL, Krischer J. Multiple autoantibodies as predictors of Type 1 diabetes in a general population. Diabetologia 2003; 46:873–74.
10. Yu L, Boulware DC, Beam CA et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012; 35:1213–8.
11. Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473–9.
12. Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151–6.
13. Gianani R, Rabin DU, Verge CF et al. ICA512 autoantibody radioassay. Diabetes 1995; 44:1340–4.
14. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1996; 93:6367–70.
15. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104:17040–5.
16. Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science (New York, NY) 1983; 222:1337–9.
17. Brooking H, Ananieva-Jordanova R, Arnold C et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003; 331:55–9.
18. Chen S, Willis J, Maclean C et al. Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65. Clin Chim Acta 2005; 357:74–83.
19. Petruzelkova L, Ananieva-Jordanova R, Vcelakova J et al. The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus. Diabet Med 2014; 31:165–71.
20. Pugliese A, Yang M, Kusmarteva I et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes 2014; 15:1–9.
21. Gianani R, Putnam A, Still T et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab 2006; 91:1855–61.
22. Maniatis AK, Yu L, Miao D, Nelson K, Eisenbarth GS. Rapid assays for detection of anti-islet autoantibodies: implications for organ donor screening. J Autoimmun 2001; 16:71–6.
23. Batstra MR, Bruining GJ, Aanstoot HJ. Antibody screening in a population of children. Ann Med 1997; 29:453–60.
24. Batstra MR, Petersen JS, Bruining GJ et al. Low prevalence of GAD and IA2 antibodies in schoolchildren from a village in the southwestern section of the Netherlands. Hum Immunol 2001; 62:1106–10.
25. Bingley PJ, Bonifacio E, Shattock M et al. Can islet cell antibodies predict IDDM in the general population? Diabetes Care 1993; 16:45–50.
26. Knip M, Korhonen S, Kulmala P et al. Prediction of type 1 diabetes in the general population. Diabetes Care 2010; 33:1206–12.
27. Kupila A, Muona P, Simell T et al. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 2001; 44:290–7.
28. LaGasse JM, Brantley MS, Leech NJ et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002; 25:505–11.
29. Pinhas-Hamiel O, Sprecher E, Vardi P. How does antibody combination really predict IDDM in the general population? Fortune telling – not fortune spending. Diabetes Metab Rev 1998; 14:252–4.
30. Schatz D, Krischer J, Horne G et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest 1994; 93:2403–7.
31. Schlosser M, Strebelow M, Rjasanowski I, Kerner W, Wassmuth R, Ziegler M. Prevalence of diabetes-associated autoantibodies in schoolchildren: the Karlsburg Type 1 Diabetes Risk Study. Ann NY Acad Sci 2004; 1037:114–7.
32. Siljander HT, Veijola R, Reunanen A, Virtanen SM, Akerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007; 50:2272–5.
33. Strebelow M, Schlosser M, Ziegler B, Rjasanowski I, Ziegler M. Karlsburg Type I diabetes risk study of a general population: frequencies and interactions of the four major Type I diabetes-associated autoantibodies studied in 9419 schoolchildren. Diabetologia 1999; 42:661–70.
34. Bingley PJ, Williams AJ. Islet autoantibody testing: an end to the trials and tribulations? Diabetes 2013; 62:4009–11.